The White House said Friday it\u2019s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the administration works to expand the site as part of its push to lower drug prices.<\/p>\n
The drugs, from German drugmaker Boehringer Ingelheim, are Jentadueto and Jentadueto XR, for Type 2 diabetes, as well as the COPD drug Striverdi Respimat.<\/p>\n
According to the White House, the diabetes drugs list for about $525 but are priced on TrumpRx starting around $55, while the COPD drug is listed at about $35, down from roughly $276. <\/p>\n
One of the diabetes drugs, Jentadueto, has a generic version that is typically cheaper. For the other drugs, discount prices listed on GoodRx tend to be higher. <\/p>\n
\u201cThose are pretty significant discounts,\u201d said Ben Link, a contributor at 46brooklyn, a nonprofit group that tracks prescription drug prices. <\/p>\n
Even for Jentadueto, patients typically pay about $25 to $35 at the pharmacy counter for the generic \u2014 meaning the TrumpRx price is still competitive, Link said.<\/p>\n
The addition comes as the White House continues to build the platform, which launched in January<\/a> as part of President Donald Trump\u2019s broader push to address soaring health care costs.<\/p>\n But the site has faced criticism<\/a> for its limited scope, with fewer than 60 drugs listed and discounts that can\u2019t be used with insurance or go toward a deductible. It also primarily offers discounts on brand-name drugs, many of which have cheaper generic equivalents. Similar prices can also be found on other discount sites. <\/p>\n It’s unclear how many people have used TrumpRx discounts to buy prescription drugs. A survey published last week<\/a> by KFF found that awareness of the site was on the lower end, with about a third of people who take prescription drugs saying they had heard at least something about TrumpRx. Of those, just 7% said they had visited the site to compare prices. That rose to about 16% among people who take GLP-1 medications.<\/p>\n The White House has declined to say<\/a> how many people have visited the site since it launched. <\/p>\n